Latest News & Features
Americas
Law firm Merchant & Gould has hired Alireza Behrooz as a partner in the firm’s chemical and life sciences group in Washington, DC. 10 December 2015
Big Pharma
The application of supplementary protection certificates to the unitary patent system poses numerous complexities, both legal and practical, as Christopher Stothers and Paul Abbott of Arnold & Porter describe. 10 December 2015
Americas
AstraZeneca has agreed to let distributor Perrigo Company sell its Entocort (budesonide) drug. 9 December 2015
Generics
Unimed Pharmaceuticals, a subsidiary of life sciences company AbbVie, has slammed generics maker Sandoz with a lawsuit alleging infringement of 11 of its patents. 8 December 2015
Americas
The US government has asked pharmaceutical company Mylan to testify with information on the price of a generic antibiotic product it makes. 7 December 2015
Americas
Valeant Pharmaceuticals has slammed Allergan’s attempt to market a generic version of its Relistor (methylnaltrexone bromide) drug. 4 December 2015
Americas
There were no surprises, but plenty of alarms yesterday following the US Court of Appeals for the Federal Circuit’s decision to reject Sequenom’s request for a re-hearing of its dispute with Ariosa Diagnostics en banc. 3 December 2015
Europe
The unitary patent and UPC would still go ahead, but what would be the impact for the life sciences sector if the UK voted to leave the EU? Victoria Bentley and Helen Cline of Pinsent Masons investigate. 3 December 2015
Americas
Following the Federal Circuit’s ruling in Amgen v Sandoz, biosimilar applicants should weigh up several factors when deciding whether to opt into the so-called patent dance. Gerard Norton and Michael Montgomery of Fox Rothschild discuss the potential strategies. 3 December 2015
Americas
The US Court of Appeals for the Federal Circuit has rejected Sequenom’s petition to re-hear its dispute with Ariosa Diagnostics en banc. 2 December 2015